PA
PMVP icon

Perceptive Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Perceptive Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-125,000
Closed -$2.89M – 148
2021
Q4 		$2.89M Sell
125,000
-176,714
-59% -$4.27M 0.04% 130
2021
Q3 		$8.99M Sell
301,714
-444,843
-60% -$14.2M 0.13% 107
2021
Q2 		$25.5M Hold
746,557
– – 0.33% 75
2021
Q1 		$24.6M Sell
746,557
-138,999
-16% -$5.48M 0.31% 69
2020
Q4 		$54.5M Buy
885,556
+280,000
+46% +$11M 0.58% 42
2020
Q3 		$21.5M Buy
+605,556
New +$22.3M 0.31% 66

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Perceptive Advisors's PMVP Position: Q1 2022 in Review

Perceptive Advisors sold out of PMV Pharmaceuticals (PMVP) in Q1 2022, closing a stake of 125,000 shares — an estimated $2.89M sold.

Perceptive Advisors first reported a position in PMVP in Q3 2020 and held it in 6 quarters. The position peaked at $54.5M in Q4 2020. 99 funds tracked by Wall St. Rank hold PMVP as of Q1 2022.

  • Perceptive Advisors reported no remaining PMV Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Perceptive Advisors sold 125,000 PMV Pharmaceuticals shares in Q1 2022, an estimated $2.89M.
  • Perceptive Advisors first reported a position in PMV Pharmaceuticals in Q3 2020 and held it in 6 quarters.
  • Perceptive Advisors's PMV Pharmaceuticals position peaked at $54.5M in Q4 2020.
  • 99 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2022.

Based on Perceptive Advisors's 13F filing for Q1 2022, filed 16 May 2022.